36729-27-8Relevant articles and documents
Copper(II) catalyzed aromatization of tetrahydrocarbazole: An unprecedented protocol and its utility towards the synthesis of carbazole alkaloids
Dalvi, Bhakti A.,Lokhande, Pradeep D.
supporting information, p. 2145 - 2149 (2018/05/08)
An efficient protocol for the aromatization of tetrahydrocarbazole is described by using catalytic copper(II) chloride dihydrate in DMSO. This newly established methodology has utilized towards the synthesis of naturally occurring carbazole alkaloids, namely 3-methylcarbazole, 3-formyl carbazole, glycozoline, glycozolicine and clauszoline-K. In addition, the protocol is generalized for the aromatization of N-substituted tetrahydrocarbazole, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline and 1,2,3,4-tetrahydro β-carboline to give the corresponding heteroaromatic compounds from very good to excellent yield. Moreover, this method has been proven to be tolerant to a broad range of functional groups with excellent yields.
FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS
-
Page/Page column 31; 32, (2016/02/26)
The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a disease or disorder, such as a proliferative disease (preferably cancer), using compounds of the invention.
Discovery of ITX 4520: A highly potent orally bioavailable hepatitis C virus entry inhibitor
Mittapalli, Gopi Kumar,Zhao, Fang,Jackson, Andrew,Gao, Hongfeng,Lee, Haekyung,Chow, Stephine,Kaur, Maninder Pal,Nguyen, Natalie,Zamboni, Robert,McKelvy, Jeffrey,Wong-Staal, Flossie,MacDonald, James E.
scheme or table, p. 4955 - 4961 (2012/09/07)
The manuscript reports an identification of a highly potent, orally bioavailable hepatitis C virus entry inhibitor through optimization of a previously reported class of molecules (1) that were not stable in the rat plasma. Compound 39 (ITX 4520) exhibited an excellent PK profile in both rats and dogs with good oral exposure, half-life and oral bioavailability. The compound is also well-tolerated in the preliminary in vivo toxicity studies and has been selected as a pre-clinical candidate for our HCV clinical pipeline.